Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tipifarnib by Kura Oncology for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase III for Peripheral T-Cell Lymphomas (PTCL). According to...
Risk adjusted net present value: What is the current valuation of Kura Oncology's Tipifarnib?
Tipifarnib is a small molecule commercialized by Kura Oncology, with a leading Phase III program in Peripheral T-Cell Lymphomas (PTCL)....
Tipifarnib by Kura Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Tipifarnib by Kura Oncology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Recurrent Head And Neck Squamous Cell...